Evidence map›Paper›PMID 27906864›Full record

ReviewCurrent opinion in pediatrics2017

Potential for treatment and a Zika virus vaccine.

Natalie Quanquin, Lulan Wang, Genhong Cheng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. A review on Zika virus outbreak, epidemiology, transmission and infection dynamics.Journal of biological research (Thessalonike, Greece) · 2020
    Review
  4. Zika clinical updates: implications for pediatrics.Current opinion in pediatrics · 2018
    Review
  5. Microcephaly in Zika Virus Infection.Annals of pediatrics & child health · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Natalie QuanquinaDepartment of Microbiology, Immunology and Molecular Genetics bMolecular Biology Interdepartmental Program, University of California, Los Angeles, California, USA cCenter of System Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing dSuzhou Institute of Systems, Suzhou, Jiangsu, China.
Lulan Wang
Genhong Cheng
Chinese Academy of Medical Sciences & Peking Union Medical College · CNUniversity of California, Los Angeles · US

Funding

Viral Mediated Type I Interferon InductionR01AI069120 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG · 2006 to 2021
$6.0M
Mechanisms of Biodefense By Toll-Like ReceptorsR01AI056154 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG · 2004 to 2014
$3.7M
Role of IRF3 and RXRa Crosstalk in Host Response to Viral InfectionsR01AI078389 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG · 2009 to 2013
$1.8M
TRANSLATIONAL AIDS AND VIRAL PATHOGENESIS TRAINING (51)T32AI089398 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, OTTO O · 2010 to 2017
$1.6M
Role of IRF3 and RXRa Crosstalk in Host Response to Viral InfectionsR56AI078389 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG · 2008 to 2008
$385k
NIAID NIH HHS R01 AI056154NIAID NIH HHS R01 AI069120NIAID NIH HHS R01 AI078389NIAID NIH HHS R56 AI078389NIAID NIH HHS T32 AI089398
6 · The paper itself

Abstract

purpose of reviewZika virus (ZIKV) has only recently been exposed as a significant public health threat, and much of our limited knowledge of its pathogenesis and triggered immune responses were discovered in only the last few years. There are currently no ZIKV-specific therapeutics or vaccines available. This review seeks to bring the reader up-to-date with the latest developments in finding a way to combat this emerging infectious disease. RECENT

findingsCurrent strategies used for developing ZIKV vaccines or treatments follow proven methods used against other flaviviruses. Unfortunately, ZIKV carries many unique challenges, such as the need to target drugs and vaccines towards immunocompromised populations (pregnant mothers and fetuses), the risk of stimulating harmful immune responses (either autoimmune or antibody-dependent enhancement of infection in those with previous flavivirus exposure), frequently silent infection that may delay treatment and increase risk of transmission to others, and multiple routes of transmission (arthropod vector, sexual, bloodborne, and potentially other body fluids). SUMMARY: Current medical recommendations are directed towards resolving symptoms and not the actual infection; however, ZIKV treatments and vaccines are in development. Vector control and travel restrictions to endemic areas may remain our only available interventions for some time.

Indexed as

Viral VaccinesAntiviral AgentsHumansZika Virus InfectionAntiviral AgentsViral Vaccines

Identifiers

PMID27906864
PMCPMC5963532
OpenAlexW2559109818

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.